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Prug-Eluting Stent Restenosis
he Pattern Predicts the Outcome
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OBJECTIVES We sought to determine if the angiographic pattern of in-stent restenosis in drug-eluting
stents (DES) maintains its prognostic importance.
BACKGROUND The pattern of restenosis in the bare-metal stent era had a significant impact on therapeutic
outcomes.
METHODS We identified a total of 250 consecutive restenotic lesions in 203 patients (66.4% sirolimus-
eluting stents and 33.6% paclitaxel-eluting stents). We divided these lesions into two groups:
focal, defined as 10 mm, 163 lesions (65.2%); and nonfocal, which were diffuse,
proliferative, or obstructive, 87 lesions (34.8%). The end points analyzed were angiographic
restenosis and target lesion revascularization (TLR).
RESULTS Diabetes was the only clinical variable associated with the pattern of restenosis (28.8% focal
compared with 52.9% diffuse; p  0.0001). Angiographic follow-up of the treatment of
restenosis was available in 61.2% of the lesions and was similar between the two groups. The
rate of angiographic restenosis was 17.8% in the focal group and 51.1% in the nonfocal group
(p  0.0001). The incidence of TLR also increased with the type of restenosis treated (9.8%
and 23%, respectively; p  0.007). An adjusted multivariate analysis revealed that the pattern
of restenosis remained associated with both the occurrence of restenosis and TLR (odds ratio
[OR] 5.1 [95% confidence interval (CI) 1.1 to 23], p  0.03; and OR 3.61 [95% CI 1.2 to
10.9], p  0.02; respectively).
CONCLUSIONS Similar to bare-metal stent data, the angiographic pattern of restenosis following DES
implantation is prognostically important. Diabetes is a significant predictor of the pattern of
restenosis in the DES era. (J Am Coll Cardiol 2006;47:2399–404) © 2006 by the























the two commercially available drug-eluting stents (DES)—
irolimus-eluting (SES) (Cypher, Cordis/Johnson & John-
on, Warren, New Jersey) and paclitaxel-eluting (PES)
Taxus, Boston Scientific, Natick, Massachusetts)—have
ramatically reduced the rate of restenosis (1–8). Not only
s restenosis less common, but it is also more likely to be
ocal than nonfocal (2,7,9,10).
Traditionally focal restenosis has a more benign prognosis
11). Whether this hypothesis remains true in the drug-
luting stent (DES) era is currently unknown.
ETHODS
etween October 2002 and October 2004 all patients
reated for DES restenosis were prospectively entered into a
edicated database. In-stent restenosis (ISR) was defined
s a luminal stenosis of 50% by quantitative coronary
ngiography located within the stent or within 5 mm of the
tent edges. We divided the lesions into two groups: focal
nd nonfocal. Focal ISR lesions were defined as10 mm in
ength and positioned at the body of the stent, the proximal
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006, accepted February 21, 2006.r distal margin, or a combination of these sites (multifocal
SR). Nonfocal ISR comprised diffuse intrastent (lesions
10 mm in length and confined to the stent), diffuse prolif-
rative (lesions10 mm in length and extending beyond the
argins of the stent), and occlusive lesions.
There were no exclusion criteria. Patients provided signed
nformed consent for the procedure and to allow the data to
e utilized for research purposes. Procedural anticoagulation
nd antiplatelet therapy followed standard protocols (12).
nterventional approach and the choice of therapy for the
estenotic lesion were at the operator’s discretion.
Clinical follow-up was performed by telephone contact or
ffice visit at 1, 6, 9, and 12 months after the index
rocedure. Angiographic follow-up was suggested for all
atients at nine months after procedure. We analyzed target
esion revascularization (TLR) and angiographic restenosis
alculated on a per-lesion basis. Cardiac death, myocardial
nfarction, target vessel revascularization (TVR), and major
dverse cardiac events (MACE) were considered secondary
nd points. The MACE was defined as a composite of
eath, myocardial infarction, and TVR, which was evalu-
ted on a per-patient basis.
All deaths were considered cardiac unless otherwise
ocumented. A non–Q-wave myocardial infarction was
efined as a total creatine kinase elevation of greater than
wo times the upper limit of normal in combination with an
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Patterns of DES Restenosis June 20, 2006:2399–404levation was associated with the development of a new
athologic Q-wave it was considered to be a Q-wave
nfarction. A TLR was defined as repeat revascularization
econdary to a stenosis 50% within the stent or within the
mm borders proximal or distal to the stent edge at the
ollow-up angiogram. A TVR was defined as repeat revas-
ularization of the target vessel.
uantitative coronary angiography analysis. Coronary
ngiograms were analyzed off line using validated edge-
etection system (CMS, Version 5.2, Medis, Leiden, the
etherlands). Minimal lumen diameter, reference vessel
iameter, and percentage diameter stenosis at baseline,
ost-procedure, and follow-up were measured. Late lumen
oss was defined as the difference between the minimal
umen diameter immediately after the procedure and at
ollow-up (13). Angiographic restenosis was defined as
iameter stenosis 50% by quantitative coronary angiogra-
hy within a previously stented segment (stent and 5 mm
roximal and distal) at the follow-up angiogram.
tatistical analysis. Continuous variables are presented as
ean  standard deviation or median (interquartile range
IQR]) and categorical variables as frequency (%). Data
nalysis was carried out according to a pre-established plan.
ifferences in proportions were tested with chi-square test
r Fisher exact test, whereas differences in location param-
ters of continuous variables were tested with Student t test
r Wilcoxon rank sum test. Fisher exact test was used when
he parametric assumptions underlying chi-square did not
old (conventionally when the number of events in one or
ore classes is 5). Wilcoxon rank sum test was used when
he parametric assumptions underlying Student t did not
old (in general when data are expressed as scores or when
t is universally accepted that they are not normal distrib-
ted). All the categoric variables were compared with
hi-square test, apart from prior brachytherapy, previous
ultiple restenosis, periprocedural myocardial infarction,
ardiac death, and follow-up myocardial infarction. All
ontinuous variables were compared using Student t test,
part from late loss.
The main purpose of our statistical analysis was to test the
ssociation between the pattern of restenosis (focal or
onfocal) and events (restenosis rate and TLR). To avoid
Abbreviations and Acronyms
BMS  bare-metal stents
DES  drug-eluting stents
IQR  interquartile range
ISR  in-stent restenosis
MACE  major adverse cardiac events
PES  paclitaxel-eluting stents
SES  sirolimus-eluting stents
TLR  target lesion revascularization
TVR  target vessel revascularizationias due to causal confounding effects of extraneous vari- (bles, a stratified logistic regression analysis was carried out
sing selected potential confounding factors as stratification
ariables (diabetes mellitus, stent diameter at index, stent
ength at index, lesion length, and type of stent that
estenosed). Confounding factors were detected both on an
pidemiologic basis, by selecting variables based on prior
udgments of their clinical relevance, and on a statistical
asis, by testing for the relation to both the exposure
pattern of restenosis) and the outcome (restenosis or TLR)
14). The p value used as a cut-off to define potential
onfounder on statistical basis was 0.10. Stent diameter at
ndex, stent length at index, and lesion length were found
tatistically associated to the independent variable (pattern
f restenosis) and to both outcomes (restenosis and TLR),
hereas diabetes and type of stent that restenosed were
ound statistically associated to the independent variable
nd to restenosis only.
Because observations recorded in the same patient cannot
e considered independent, the sandwich estimator of
ariance-covariance matrix was used to take into account
lustered data (more lesions within the same subject). The
ariance-covariance matrix of odds ratio (OR) estimates is
btained by default with every statistical software package.
he sandwich version of the variance-covariance matrix,
lso called “robust covariance-matrix” is provided as an
ption only by specialized software (SAS Institute, Cary,
orth Carolina) (15).
The results were reported as adjusted OR with associated
5% confidence interval (CI) and p value. The Statistical
nalysis System program version 9.1 (SAS Institute) was
sed for data analysis.
ESULTS
uring the study period a total of 250 lesions in 203
atients were treated; 65.2% (163) were focal and 34.8%
87) were nonfocal. Of the nonfocal lesions, 24.3% were
iffuse, 2.4% proliferative, and 8% obstructive. Baseline
emographic and procedural data are presented in Table 1.
he only differences between the two groups were a higher
ncidence of diabetes mellitus, a longer stent length, and an
ncreased likelihood of the index lesion being an occlusion
n the group treated for nonfocal restenosis. During the
rocedure, operators implanted another DES in 69% of
onfocal lesions versus 57.1% of focal lesions (p  0.043).
ntravascular ultrasound use and balloon inflation pressures
ere similar, although the maximum balloon diameter was
arger in the focal group.
uantitative angiographic analysis. Serial quantitative
oronary angiography data are shown in Table 2. Angio-
raphic follow-up was available in 101 lesions in the focal
roup (64.3%) and 47 lesions (55.3%) in the nonfocal group
p  0.57) (Fig. 1). There was a highly significant difference
n restenosis rates following retreatment between the groups
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June 20, 2006:2399–404 Patterns of DES Restenosisas confirmed following adjustment for potential con-
ounding variables (OR 5.0 [95% CI 1.1 to 23.0]; p 0.03).
he late lumen loss was lower in the focal group (0.46 [IQR
.11 to 0.83] compared with 1.08 [IQR 0.14 to 1.8]; p 
.007). The pattern of subsequent restenosis at follow-up
emained the same in 50%, became worse in 26.2%, and
mproved in 23.8% (Fig. 2). Because the restenosis rate was
o high in the nonfocal group, we carried out a subgroup
nalysis to determine if there were any features associated
ith the risk to develop a second restenosis in this group.
he only difference was a numerically higher use of balloon
ngioplasty for the treatment of the nonfocal lesions that
eveloped a second restenosis. Of the 24 lesions with
onfocal pattern that developed a second restenosis, 9 of
hem were treated with conventional (“plain old”) balloon
ngioplasty (POBA) while only 4 of 23 lesions which did
ot develop a second restenosis were treated with POBA
t the time of the initial restenosis (37.5% vs. 17.4 %;
 0.19).
linical outcomes. There were no in-hospital deaths or
able 1. Baseline Clinical and Procedural Characteristics of the




atients n  132 n  71
ge (yrs) 62.7  10 64.4  9 0.26
ale gender 90.9% 78.9% 0.3
jection fraction (%) 52.9  9.6 51.2  10.9 0.25
revious MI 43.5% (57) 51.4% (36) 0.3
revious CABG 29.5% (38) 24.6% (17) 0.51
isk factors
Family history 43.8% (56) 46.4% (32) 0.76
Hypertension 63.4% (83) 67.6% (48) 0.64
Hypercholesterolaemia 71.8% (94) 71.4% (50) 1.0
Current smoker 16.2% (21) 11.6% (8) 0.53
Diabetes mellitus 25.4% (33) 47.9% (34) 0.002
esion characteristics at initial
DES implantation
n  163 n  87
De novo 76.7% (125) 82.8% (72) 0.33
Previous BMS ISR 23.3% (38) 17.2% (15) 0.33
Previous brachytherapy 1.2% (2) 3.4% (3) 0.34
Previous multiple ISR 3.7% (6) 3.4% (3) 1.0
Occlusion 7.4% (12) 25.3% (22) 0.0001
etails of DES that restenosed
Sirolimus-eluting 69.9% 59.8% 0.122
Paclitaxel-eluting 30.1% 40.2% 0.122
Stent diameter 2.9  0.30 2.9  0.34 0.99
Stent length 29.56  12.6 35.74  18.25 0.002
reatment of DES restenosis
Repeat DES implantation 57.1% 69% 0.043
POBA 42.9% 31% 0.043
Max balloon diameter (mm) 3.15  0.42 3.01  0.43 0.012
Max inflation pressure (atm) 16.35  4.7 16.21  3.9 0.8
IVUS 30.7% 34.5% 0.57
ata are presented as percentage (n) or mean  standard deviation, unless otherwise
pecified.
BMS  bare-metal stent; CABG  coronary artery bypass graft; DES 
rug-eluting stent; ISR  in-stent restenosis; IVUS  intravascular ultrasound;
I  myocardial infarction; POBA  “plain old” balloon angioplasty.eriprocedural revascularizations (Table 3). Two patients, voth in the focal group, developed a periprocedural non–
-wave myocardial infarction. Median clinical follow-up
as 13.7 months (IQR 10.7 to 19), and only one patient (in
he focal group) was lost to follow-up. The TLR rate was
.8% in the focal group compared with 23% in the nonfocal
roup (p  0.007), and no patients required surgical
evascularization (Fig. 3). Again, adjustment for potential
onfounding variables confirmed our results (OR 3.6 [95%
I 1.1 to 10.9]; p  0.02).
For focal restenotic lesions, the TLR rate following
epeated DES implantation was 8.6% compared with 11.4%
ollowing POBA (p  0.6). For nonfocal restenotic lesions,
he TLR rate following DES implantation was 22.6% and
ollowing POBA 24% (p  1.0).
ISCUSSION
he main findings of this report are: 1) the pattern of DES
estenosis is a predictor of the need for subsequent reinter-
ention; and 2) diabetes mellitus remains a significant
redictor of the pattern of restenosis.
When analyzing our data, we chose to divide the lesions
nto two groups: focal and nonfocal. We took this approach
ecause of the relatively low incidence of proliferative and
cclusive restenosis which could have limited the accuracy
f our analysis. This higher prevalence of focal restenosis
oncurs with previous studies (2,7,9,10).
Our data show for the first time that the pattern of
estenosis retains its prognostic importance in the era of
ES implantation. Similarly to the Mehran et al. (11) data,
urs have shown that the incidence of TLR increases with
he severity of the pattern of restenosis treated. In the
resent study, there is a corresponding increase in angio-
raphic restenosis. This should be interpreted cautiously
able 2. Quantitative Coronary Angiographic Data
Focal Nonfocal p Value
re-procedure 163 87
RVD (mm) 2.97  0.5 2.65  0.61 0.0001
MLD (mm) 1.05  0.45 0.8  0.49 0.0001
DS (%) 64.6  13 69.6  17.7 0.014
esion length (mm) 9.1  5.3 15.3  9.7 0.0001
ost-procedure
RVD (mm) 3.2  0.52 2.99  0.51 0.002
MLD (mm) 2.77  0.57 2.56  0.49 0.003
DS (%) 13.6  9.3 13.8  8.4 0.896
ollow-up 101 47
RVD (mm) 3.1  0.46 2.82  0.57 0.006
MLD (mm) 2.26  0.77 1.46  1.05 0.0001
DS (%) 26.9  21.6 49.8  33 0.0001
edian late loss (mm) 0.46 (0.11–0.83) 1.08 (0.14–1.8) 0.007
ean late loss (mm) 0.59  0.71 1.13  1.03 0.0001
ngiographic restenosis 17.8% (18/101) 51.1% (24/47) 0.0001
ata are presented as mean  standard deviation or median interquartile range
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Patterns of DES Restenosis June 20, 2006:2399–404wing to the low rate of angiographic follow-up, which can
rtificially elevate the incidence of angiographic restenosis.
espite this caveat it is important to point out that the two
roups had similar follow-up rates. It is interesting to note
hat in the Mehran et al. (11) work diabetes mellitus and the
ccurrence of previous restenosis were important predictors
f TLR. In fact, both were more significant predictors than
he pattern of restenosis, with odds ratios of 2.8 and 2.7,
igure 1. Clinical status and results of noninvasive functional tests in patien
cintigraphy or stress echocardiogram.Figure 2. Pattern of restenosis at baseline and follow-up of thespectively, whereas the odds ratio for the pattern of
estenosis was 1.7. In contrast, in our data the pattern of
estenosis was the only significant predictive factor of TLR
n multivariate analysis (p  0.02).
This data has important implications in the management
f these patients who by definition have already failed our
urrent best therapy. Currently little data are available on
he optimal management of DES restenosis (16). It is
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June 20, 2006:2399–404 Patterns of DES Restenosisarticularly relevant to any discussion of the management of
ES restenosis that we consider that in the bare-metal stent
ra the TLR rate of focal restenosis was between 19% and
5% (11,17). The corresponding TLR rate in our experience
igure 3. Clinical status and results of noninvasive functional tests in pati
able 3. In-Hospital and Follow-Up Clinical Events in the
otal Cohort, According to the Pattern of Restenosis
Focal Nonfocal p Value
rocedural/in-hospital death 0 0 —
rocedural/in-hospital CABG 0 0 —
eriprocedural MI 1.5% (2) 0 0.54
cute thrombosis 0 0 —
linical follow-up (days) 447  218 447  214 0.99
ubacute thrombosis 0 0 —
ate thrombosis 0 0 —
ACE 18.9% (25) 29.6% (21) 0.11
ardiac death 3% (4) 4.2% (3) 0.69
I at follow-up 0 2.8% (2) 0.12
VR (per patient) 15.9% (21) 22.5% (16) 0.25
LR (per patient) 11.4% (15) 22.5% (16) 0.04
VR (per lesion) 14.7% (24) 23% (20) 0.12
LR (per lesion) 9.8% (16) 23% (20) 0.007
ata are presented as percentage and absolute numbers.
CABG  coronary artery bypass graft; MACE  major adverse cardiac events;
I  myocardial infarction; TLR  target lesion revascularization; TVR  target
essel revascularization.ST  stress EKG or myocardial scintigraphy or stress echocardiogram; ISR 
escending; QCA  quantitative coronary angiography; RCA  right coronars 9.8%, and even when the pattern is nonfocal the 23%
LR rate represents a significant improvement.
The different strategies used by the operators in this
tudy including repeat DES implantation were all safe
ith a very low rate of periprocedural MACE and no
pisodes of subacute or late thrombosis. The optimal
ercutaneous treatment of DES restenosis remains un-
lear, and our data do not demonstrate any clear advan-
age for either modality.
tudy limitations. This study has the limitations inherent
o the analysis of retrospective data; however, it is difficult to
ee how these data could be obtained in a randomized
ashion. Another limitation is the low rate of angiographic
ollow-up, albeit similar in the two groups. The majority of
atients who refused angiography were clinically stable
91% asymptomatic) and had negative noninvasive tests for
schemia. This cohort of patients has undergone many
rocedures and are understandably reluctant to return for
ngiography in the absence of symptoms or noninvasive
vidence of ischemia.
onclusions. From this analysis of restenotic DES lesions
e can conclude that the pattern of restenosis retains its
mportance in the DES era and that diabetes mellitus
emains predictive of the pattern of restenosis.
ith and without target lesion revascularization (TLR). CX  circumflex;ents w
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